Comparing the current results to its competitors, Catalent Inc reported Revenue increase in the 1 quarter 2024 by 4.18 % year on year. The sales growth was above Catalent Inc 's competitors' average revenue growth of 0.98 %, achieved in the same quarter.
Catalent Inc 's Comment on Competition and Industry Peers
The company is a holding company that owns Catalent Pharma Solutions, Inc., which holds all operating assets. It has invested several billion dollars to expand manufacturing and development capabilities to serve the biopharmaceutical, pharmaceutical, and consumer health industries. The company has also hired and trained thousands of manufacturing associates to support its operations.
Overall company revenue, increased by 4.18 % faster than Catalent Inc 's competitors within this division and its market share improved to approx. 7.4 %. << More on CTLT Market Share.
*Market share is calculated based on total revenue.
July 16, 2024
Catalent s $25 Million Expansion Elevates European Clinical Supply Expertise in Schorndorf Catalent, Inc. (NYSE: CTLT), a global leader in enabling the development and supply of better treatments for patients worldwide, proudly announces the completion of a significant expansion of its clinical supply facility located in Schorndorf, Germany. This state-of-the-art facility, Catalent s flagship site in Europe, has been augmented to better meet the growing demands of the clinical trial supply chain.This $25 million investment extends the facility s footprint by an additional 32,000 square feet (approximately 3,000 square meters), cementing Catalent s commitment to providing comprehensive clinical supply service...
Cryoport Inc's business model revolves around providing temperature-controlled logistics solutions for the shipping of cryogenic products, including life sciences materials, cell and gene therapies, and reproductive medicine. The company utilizes its advanced technology and a global network of partners to ensure safe and secure transportation of these sensitive materials, catering to the needs of the rapidly growing biopharmaceutical industry.
Alpha Teknova Inc is a biotechnology company that operates on a business model centered around the development and production of custom reagents, enzymes, and other consumables for the life sciences industry. They provide tailored solutions to meet the specific needs of their clients by leveraging their expertise in molecular biology and protein sciences. By partnering with research institutions and biotech companies, they aim to support advancements in genomics, proteomics, and drug discovery.
Marizyme Inc operates on a business model that focuses on developing and commercializing innovative therapies derived from marine sources. The company utilizes enzymatic technologies to create effective and sustainable solutions for various medical applications and is committed to improving patient outcomes by advancing the development of novel therapeutics. Marizyme aims to establish partnerships and collaborations with healthcare organizations and pharmaceutical companies to bring its products to market efficiently and effectively.
Evotec SE is a German drug discovery and development company that operates on a contract research organization (CRO) business model. They offer a comprehensive range of services to pharmaceutical and biotechnology companies, including target identification and validation, hit identification, and lead optimization. Through collaborations and partnerships, Evotec aims to accelerate the discovery and development of new drugs and therapies.
Charles River Laboratories International inc Share Performance
+42.53%
This Year
Charles River Laboratories International inc
Profile
Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.
Sources:
Catalent Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Catalent Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
